All the patients were either GH-deficient or GH-insufficient and had a significant greater occurrence of dyslipidemia, insulin resistance, increased fat mass and a marked reduction in cardiac dimensions and performance [29]. This evidence concerns the gene GH1 and metabolic syndrome.